Skip to content
The Senate Commerce Committee approved legislation yesterday which prohibits pharmacy benefit managers (PBMs) from pocketing the rebates they collect from drug makers. The bill […]
PBM Transparency Act now heads to full Senate Read More »
Government policy impacting biotech—including drug price controls, pharmacy benefit managers (PBMs), accelerated approval, and support for new antibiotics—received a public airing this week when
As Moderna CEO Stéphane Bancel heads to Capitol Hill to testify before the Health, Education, Labor, and Pensions (HELP) Committee, experts are watching to
To protect innovation, we need to protect Bayh-Dole, says one expert Read More »
On Wednesday, Moderna’s CEO will testify before the Senate Health, Education, Labor, and Pensions (HELP) Committee in a hearing with a misleading title, “Taxpayers
4 questions with Moderna President Stephen Hoge Read More »
While animal activists oppose animal testing on moral grounds, the biotech industry knows that alternative technology can provide more accurate and less expensive screening
Biotech wants to reduce animal testing and FDA is now tasked with helping Read More »
Two issues critical for the biotech sector kept busy Capitol Hill on March 16: the collapse of Silicon Valley Bank (SVB) and Mexico’s biotech
SVB collapse and Mexico corn ban consultations keep Capitol Hill busy Read More »
The makers of more than a dozen prescription drugs covered by Medicare are seeing the first impacts of the Inflation Reduction Act (IRA) passed
CMS announces penalties on 27 prescription drugs, draft guidance on price controls Read More »
Agriculture is essential to the U.S. economy – and to put food on the table for American families. And more than ever, it’s critical
Plant Biostimulant Act would offer clear market path for important ag biotech Read More »
Biotechnology Innovation Organization (BIO) members Bristol Myers’, Pfizer’s, and AbbVie’s drugs “are likely to be among 10 big-selling medicines subject to U.S. price negotiations
U.S. drug price negotiation already affecting Bristol Myers, Pfizer, AbbVie Read More »
While it deliberates on whether to support the expansion of the international waiver of IP protections for COVID-19 therapeutics and diagnostics, the United States
Last chance for public hearing on the COVID IP waiver expansion Read More »
